GLP1 receptor agonists (GLP1RA) such as semaglutide, liraglutide, and the combined GIP/GLP1RA tirzepatide have revolutionized pharmacotherapy for obesity; initially developed for diabetes treatment, they showed better glycaemic control as well as lower body weight in treated patients and have been approved for obesity management. The gene discussed is GIP; the disease is Obesity.